Clinical and genomic features of SPOP‐mutant prostate cancer

Inactivating missense mutations in the SPOP gene, encoding speckle‐type poxvirus and zinc‐finger protein, are one of the most common genetic alterations in prostate cancer.

[1]  M. Rubin,et al.  Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us. , 2021, Trends in cancer.

[2]  O. Elemento,et al.  SPOP mutation confers sensitivity to AR-targeted therapy in prostate cancer by reshaping the androgen-driven chromatin landscape , 2021, bioRxiv.

[3]  N. Mitsiades,et al.  Genomic landscape of advanced prostate cancer in racial minority populations: Real-world experience in a safety-net hospital oncology clinic. , 2021 .

[4]  Jonathan E. Shoag,et al.  Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. , 2020, The Journal of clinical investigation.

[5]  P. Nelson,et al.  Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer , 2020, PloS one.

[6]  P. Kantoff,et al.  Racial Differences in Genomic Profiling of Prostate Cancer. , 2020, The New England journal of medicine.

[7]  N. Agarwal,et al.  Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. , 2020, European urology.

[8]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[9]  P. Kantoff,et al.  Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. , 2020, European urology.

[10]  P. Kantoff,et al.  Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer , 2020, Clinical Cancer Research.

[11]  Ed Reznik,et al.  Hyperpolarized MRI of Human Prostate Cancer Reveals Increased Lactate with Tumor Grade Driven by Monocarboxylate Transporter 1. , 2020, Cell metabolism.

[12]  E. Antonarakis,et al.  Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. , 2020, European urology.

[13]  B. Trock,et al.  Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer , 2019, JCO precision oncology.

[14]  J. Olsen,et al.  SPOP promotes transcriptional expression of DNA repair and replication factors to prevent replication stress and genomic instability , 2018, Nucleic acids research.

[15]  M. Rubin,et al.  SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity , 2018, Clinical Cancer Research.

[16]  Yi Mi Wu,et al.  The long tail of oncogenic drivers in prostate cancer , 2018, Nature Genetics.

[17]  G. Freeman,et al.  Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3SPOP to control cancer immune surveillance , 2017, Nature.

[18]  Zachary J. Heins,et al.  Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. , 2017, JCO precision oncology.

[19]  Alain Bergeron,et al.  Genomic hallmarks of localized, non-indolent prostate cancer , 2017, Nature.

[20]  Oliver Sartor,et al.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[22]  J. Shendure,et al.  Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer , 2016, Nature Medicine.

[23]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[24]  Paola Lecca,et al.  SPOP mutation leads to genomic instability in prostate cancer , 2015, eLife.

[25]  R. Eeles,et al.  Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. , 2015, European urology.

[26]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[27]  K. Rajapakshe,et al.  Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. , 2014, Cancer research.

[28]  Chris Sander,et al.  Copy number alteration burden predicts prostate cancer relapse , 2014, Proceedings of the National Academy of Sciences.

[29]  E. Buckles,et al.  Identification of speckle-type POZ protein somatic mutations in African American prostate cancer , 2014, Asian journal of andrology.

[30]  A. Hsieh,et al.  PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance , 2014, Asian journal of andrology.

[31]  H. Hieronymus,et al.  SPOP mutations in prostate cancer across demographically diverse patient cohorts. , 2014, Neoplasia.

[32]  T. Thompson,et al.  Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches , 2013, Oncogene.

[33]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[34]  M. Rubin,et al.  Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover , 2013, Proceedings of the National Academy of Sciences.

[35]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[36]  A. Sivachenko,et al.  Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.

[37]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[38]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[39]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[40]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[41]  S. Lenk,et al.  TP53 gene mutations in prostate cancer progression. , 2010, Anticancer research.

[42]  A. Ziaee,et al.  Role of PTEN gene in progression of prostate cancer. , 2007, Urology journal.

[43]  M. Ittmann,et al.  SRC-3 is required for prostate cancer cell proliferation and survival. , 2005, Cancer research.

[44]  S. Brewster,et al.  Wnt signalling and prostate cancer , 2005, Prostate Cancer and Prostatic Diseases.

[45]  E. Gelmann,et al.  Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. , 2000, Cancer research.